1. Home
  2. CLLS
  3. CLLS News

Latest Cellectis S.A. (CLLS) News on July 27, 2024

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

GlobeNewswire

a day ago

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Share on Social Networks: